How 12% Annual EBITDA Growth Targets Rewrite GTM Enablement for PE-Backed Founders

I was in a portfolio review last quarter when the operating partner dropped the new mandate: "We need 12% annual EBITDA growth to hit our 2.5x target." The room went quiet. The old playbook—leverage, cost-cutting, multiple expansion—wasn’t going to cut it anymore. Revenue growth had become the primary alpha lever, and GTM was suddenly the most scrutinized function in the board deck.

Here’s what I’ve seen work (and fail) in the first 100 days with PE-backed founders trying to hit that 12% target.

The Problem: GTM Is the Least Instrumented Function in the Portfolio

Most early-stage companies I work with have three things in common:

1. They’ve raised capital based on a compelling product vision.
2. Their GTM is still a founder-led black box.
3. They’re about to face a board that demands proof of revenue readiness.

The disconnect is brutal. Founders think in product milestones; PE partners think in EBITDA growth. Without a shared language—like a Revenue Readiness Index or a living ICP library—trust erodes fast. I’ve watched this play out in three portfolio companies this year alone.

What Actually Works in the First 100 Days

The firms hitting their targets aren’t the ones with the best sales decks. They’re the ones with the best diagnostics. Here’s the pattern:

1. Start with a 30-minute GTM diagnostic (not a 3-day workshop). I use a modified version of the framework I built at [previous company], which surfaces gaps in ICP clarity, messaging, and deal execution. It’s not perfect, but it’s repeatable.

1. Build named instruments, not one-off deliverables. A Revenue Readiness Index that travels into board reviews beats a 50-page GTM playbook every time. The best ones I’ve seen are updated monthly and benchmarked across the portfolio.

1. Tie GTM health to EBITDA growth. This sounds obvious, but most founders I work with have never had to connect their pipeline metrics to the firm’s financial model. The ones who do this early—even imperfectly—are the ones who keep their board’s trust.

The Hard Truth: Not Every Company Can Hit 12%

Here’s what the reports don’t tell you: Some companies can’t hit 12% annual EBITDA growth, no matter how good their GTM is. Maybe their market’s too niche. Maybe their product needs another 12 months. The operating partners who admit this early—and pivot to a hold-or-sell strategy—are the ones who save their LPs the most pain.

I’ve been in rooms where the diagnostic revealed a hard ceiling at 8% growth. The founder wanted to double down on GTM; the PE team needed to face reality. The best outcome? We sold the company at a 1.8x multiple instead of burning another $2M trying to force 12%.

What This Means for You

If you’re a PE operating partner or VC platform lead, here’s the non-negotiable: GTM instrumentation has to happen in the first 100 days. Not because it’s a best practice, but because the alternative is a portfolio of companies that can’t defend their revenue growth in LP reviews.

If you’re a founder, here’s the hard question: Can you prove your GTM is improving in a way that survives a leadership change? If the answer isn’t a clear yes, start building your instruments now. The firms that wait until the exit process to figure this out are the ones stuck in the backlog.

This isn’t theoretical. I’ve lived it—three times this year alone. If you’re facing the 12% mandate and want to talk through the diagnostics, I’m at brandon@andru.ai.